The Americans, the British, and the Canadians rolled up their sleeves to receive the emerging Corona vaccine, for them and their counterparts in some countries the way to get rid of the epidemic has become clear, even if it takes several months, but for poor countries, the road is long and bumpy.
The ambitious initiative called “Kovacs”, which aims to ensure that all countries receive the vaccine has been able to secure only a small portion of the nearly two billion doses it hoped to buy during the next year, and it has not yet concluded a deal to obtain vaccines, especially as it faces a shortage of funding.
It appears that the Coronavirus, which has killed more than a million and 600 thousand people, has also revealed inequality between countries, with dilapidated health systems and weak economies most affected.
The World Health Organization, the Global Vaccine Alliance, and the International Alliance to Combat Epidemics established this initiative to avoid countries competing for vaccines.
Experts believe that opportunities for equitable sharing of vaccine doses between countries have begun to diminish, especially with the limited quantities of vaccines. The developed countries that contributed to reaching these vaccines with their research funding from taxpayers’ money are under great pressure to protect their population through the purchase of vaccines.
At the same time, the poorest countries are looking for alternatives due to their fear that they will not be able to obtain the necessary vaccines to curb the spread of the epidemic among their citizens.
Arnaud Bernard, head of the global health department at the World Economic Forum, said: “Of the approximately 12 trillion doses that pharmaceutical laboratories will produce next year, about 9 billion doses have been seized by rich countries. Kovacs has not been able to secure adequate doses, and most likely they will obtain Late doses. ”
So far, the initiative has managed to reserve about 200 million doses, according to Kovacs spokesman James Volcker, noting that it had agreed to reserve another 500 million doses, but this quantity is not yet confirmed.
Kovacs will get the 200 million doses from the Serum Institute in India, the company that is likely to manufacture a large portion of the doses that will be distributed in developing countries.
Poonawala, the executive director of the institute, confirmed that he had a demand of about one hundred million doses of the vaccine developed by the University of Oxford and AstraZeneca.